Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.
Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter B
GENERIC NAME |
TRADE NAME |
CONDITION |
STUDY CODE |
STUDY NAME |
ACCESS TO STUDY / PROTOCOL |
ACCESS TO RESULTS |
---|---|---|---|---|---|---|
BACILLUS CLAUSII |
Enterogermina |
Diarrhea |
LPS16140 |
EPIC |
||
BACILLUS CLAUSII |
Enterogermina |
Diarrhea |
ENTER_L_01125 |
PADRE |
||
BACILLUS CLAUSII |
Enterogermina |
Diarrhea |
ENTER_L_01486 |
ENIGMA |
||
BACILLUS CLAUSII |
Enterogermina |
Gastrointestinal Diseases |
LPS15198 |
BASTA |
||
BACILLUS CLAUSII |
Enterogermina |
Gastrointestinal Diseases |
PM_L_0161 |
EFESO |
|
|
BACILLUS CLAUSII |
Enterogermina |
Infection |
PM_L_0199 |
DIAMANTE |
||
BACILLUS CLAUSII |
Enterogermina |
Diarrhea |
ENTERR06929 |
cadiLAc |
||
BACILLUS CLAUSII |
Enterogermina |
Diarrhea |
LPS14914 |
KIDDIE |
|
|
BACILLUS CLAUSII |
Enterogermina |
Irritable Bowel Syndrome |
ENTERL08784 |
BaclauSII |
|
|
BACTERIAL LYSATES |
Pulmonarom |
Medical Prevention Therapy |
BACLY_L_03329 |
NA |
||
BAMADUTIDE |
Not marketed |
Diabetes Mellitus, Type 2 |
DRI13940 |
NA |
||
BAMADUTIDE |
Not marketed |
Diabetes Mellitus, Type 2 |
PDY15012 |
NA |
||
BAMADUTIDE |
Not marketed |
Diabetes Mellitus, Type 2 |
PDY15264 |
NA |
||
BAMADUTIDE |
Not marketed |
Diabetes Mellitus, Type 2 |
TDR13700 |
NA |
||
BAMADUTIDE |
Not marketed |
Diabetes Mellitus, Type 2 |
TDR15516 |
NA |
||
BELUMOSUDIL |
Rezurock |
Bioavailability |
KD025-106 |
NA |
||
BELUMOSUDIL |
Rezurock |
Drug-drug Interaction Autoimmune Diseases Fibrotic Disease |
KD025-107 |
NA |
||
BELUMOSUDIL |
Rezurock |
Autoimmune Diseases Fibrosis |
KD025-108 |
NA |
||
BELUMOSUDIL |
Rezurock |
Chronic Graft Versus Host Disease (cGVHD) |
KD025-208 / ACT17631 |
NA |
||
BELUMOSUDIL |
Rezurock |
Chronic Graft Versus Host Disease (cGVHD) |
KD025-213 / DRI17633 |
NA |
||
BELUMOSUDIL |
Not Marketed |
Psoriasis Vulgaris |
KD025-205/ACT17656 |
NA |
||
BELUMOSUDIL |
Not Marketed |
Psoriasis Vulgaris |
KD025-206/DFI17657 |
NA |
||
BELUMOSUDIL |
Not Marketed |
Chronic Plaque Psoriasis |
KD025-211/EFC17658 |
NA |
||
BELUMOSUDIL |
Not Marketed |
Idiopathic Pulmonary Fibrosis |
KD025-207 / EFC17630 |
NA |
||
BELUMOSUDIL |
Rezurock |
Bioavailability |
KD025-111 |
NA |
||
BIVV001 |
Not marketed |
Hemophilia A |
TDU16220 |
NA |
||
References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted